Introduction
============

Cancer is becoming the second most common cause for death in recent years.[@b1-ott-10-945] Surgery is the main treatment for early cancer patients; adjuvant and palliative treatments are mainly used in patients with advanced cancer, involving traditional chemotherapy and targeted therapy. Pathological test of tumor tissues is the gold standard method for histological diagnosing, and detection of gene mutations in tumor tissues is a directive factor for selection of targeted drugs.[@b2-ott-10-945] For non-small cell lung cancer (NSCLC), the status of EGFR gene mutations is a sensitive and reliable biomarker for EGFR-TKIs therapy (eg, gefitinib and erlotinib).[@b3-ott-10-945],[@b4-ott-10-945] For colorectal cancer (CRC), the anti-EGFR MoAb (eg, cetuximab) is now restricted to patients with wild-type KRAS gene, and the mutation status of BRAF gene is predictive of the drug resistance of anti-EGFR MoAb in wild-type KRAS patients.[@b5-ott-10-945],[@b6-ott-10-945] At the same time, detection of other gene mutations has also been used in patients with different cancers. For diagnosing genomic mutation, biopsy and surgery of primary and metastatic tumors are the main resources of tumor tissues, but they are invasive, uncomfortable and of high cost.[@b7-ott-10-945],[@b8-ott-10-945] Thus, new non-invasive methods for gene detection are increasingly focused on.

Circulating tumor DNA (ctDNA) is tumor DNA of cell-free DNA (cfDNA) circulating in plasma or serum of cancer patients,[@b9-ott-10-945] which is \~170 bp. ctDNA originates from tumor cells, which can be identified in blood samples, and rapidly disappears after surgery or chemotherapy. The level of ctDNA is significantly higher in cancer patients than in healthy controls, which can harbor the somatic genomic alterations found in tumor tissues.[@b10-ott-10-945],[@b11-ott-10-945] Unlike tissue biopsy, obtaining a sample of ctDNA is a noninvasive approach, with less risk and lower cost. Thus, detection of ctDNA is actively being explored and provides opportunities for minimally invasive cancer diagnosis, prognosis and tumor monitoring in cancer patients.[@b12-ott-10-945]--[@b15-ott-10-945]

Many studies have been carried out to validate the possibility of ctDNA as a new source for detection of gene mutations. On the basis of this background, we decided to conduct this meta-analysis to investigate the diagnostic value of ctDNA for detection of KRAS gene mutations in CRC patients. The results will help establishing whether ctDNA can be used for detection of gene mutations in cancer patients.

Materials and methods
=====================

Literature search strategy
--------------------------

Two investigators independently searched Medline, Embase, Cochrane library and Web of Science databases for potentially relevant articles between inception and January 31, 2016. The search heading terms and keywords were "carcinoma" or "cancer" or "neoplasm", "serum" or "plasma" or "circulating", "KRAS" and "mutation", which were limited to English publications in human beings. Then, the results were manually searched for included studies and double-checked by a second investigator.

Selection criteria
------------------

We searched the full-text articles that investigated the comparison of detection of KRAS gene mutations between tumor tissue and the matched plasma or serum in CRC patients. The following publications were excluded: abstracts, news, letters, case reports and reviews. Publications retrieved from databases were first screened by titles and abstracts; full-text articles were reviewed and selected according to the inclusion criteria. The inclusion criteria were as follows: 1) CRC patients should be diagnosed by histopathological or cytological examination; 2) KRAS mutations should be detected in tumor tissue and the paired ctDNA; 3) sufficient information should be provided to conduct the statistical analysis; and 4) studies should be limited to human trials and published in English language. The study with most patients was included from those reported using the same technique by the same center.

Data extraction and quality assessment
--------------------------------------

Two investigators independently abstracted following information from each trial: name of the first author, year of publication, location where the study was performed, number of patients enrolled, stage of cancer (according to tumor--node--metastasis \[TNM\] criteria), storage method of tumor tissues, detection method of ctDNA, collection time of blood samples (before or after chemotherapy), format of blood samples (serum or plasma), true positive (TP), false negative (FN), false positive (FP) and true negative (TN). When the study included ≥2 methods of mutation detection, we used the data with the best sensitivity or specificity. The discrepancy between the 2 investigators was resolved by discussion among all the authors. Quality assessment of eligible studies was evaluated using QUADAS-2 (quality assessment of studies of diagnostic accuracy included in systematic reviews-2).

Statistical analysis
--------------------

The publication bias was detected using Deeks funnel plot, and *P*\<0.05 suggested the significant publication bias. The detection of KRAS gene mutation in tumor tissues acted as the gold standard for diagnosing gene mutation in this analysis. We calculated the sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), corresponding 95% confidence intervals (95% CIs) and area under the ROC curve (AUROC), according to the numbers of TP, TN, FP and FN. Subgroup analyses were also conducted according to different clinical data. Statistical heterogeneity was evaluated by *Q* test and inconsistency index (*I*^2^), with significant heterogeneity set at *P*≤0.05 and *I*^2^\>50%. All statistical analyses were performed using STATA software (version 12.1, StataCorp LP) with the Midas module.

Results
=======

Eligible studies
----------------

After independent searching, 6,033 records were retrieved from these databases. After reviewing the titles and abstracts, 5,977 records were excluded. After full-text articles were reviewed, 20 publications were considered to be eligible for inclusion in our analysis ([Figure 1](#f1-ott-10-945){ref-type="fig"}).[@b15-ott-10-945]--[@b34-ott-10-945] In the article reported by Morgan et al,[@b25-ott-10-945] the blood samples including serum and plasma were analyzed. Subsequently, 21 eligible studies were included for analyzing the effectiveness of ctDNA for detection of KRAS gene mutations in CRC patients.

Study characteristics
---------------------

Our analysis included 21 eligible studies, which are shown in [Table 1](#t1-ott-10-945){ref-type="table"}. In total, 5 studies were from China, 4 from France, 3 from the USA, 2 from Italy, 2 from Japan, 1 from Switzerland, 1 from multi-country, 1 from Denmark, 1 from Korea and 1 from the Netherlands. A total of 1,812 CRC patients were included. In all, 18 studies detected both codon 12 and codon 13 of KRAS gene. A total of 3 studies detected only codon 12 of KRAS gene. In all, 14 studies reported the exact collection times of both tumor tissue samples and blood samples, which were collected before chemotherapy. A total of 16 circulating blood samples were plasma and 5 samples were serum. In all, 12 formalin-fixed and paraffin-embedded (FFPE) tumor tissue samples were used for detection of KRAS gene mutations; 4 tumor tissues were frozen before detection. Various detection methods were used, in which the allele refractory mutation system -- quantitative polymerase chain reaction (ARMS-qPCR) was the most frequently reported.

Study quality
-------------

We assessed the quality of eligible studies by QUADAS-2 and found that the quality of all studies was good ([Table 2](#t2-ott-10-945){ref-type="table"}). The Deeks regression test was performed, and no significant publication bias was detected (*P*=0.060; [Figure 2](#f2-ott-10-945){ref-type="fig"}).

### Meta-analysis of specificity and sensitivity in overall population

In our analysis, the overall pooled specificity was 0.96 (95% CI =0.93--0.98), the pooled sensitivity was 0.67 (95% CI =0.55--0.78), the DOR was 53.95 (95% CI =26.24--110.92) and the AUROC was 0.95 (95% CI =0.92--0.96) ([Figure 3](#f3-ott-10-945){ref-type="fig"} and [Table 3](#t3-ott-10-945){ref-type="table"}). Specificity can quantify the ability of avoiding FPs, so the high specificity indicated high accuracy of ctDNA for detection of KRAS gene mutations. Sensitivity refers to the ability of correctly detecting patients who do have the condition. Considering the trade-off between sensitivity and specificity, AUROC is used to measure the diagnostic performance of ctDNA. When AUROC is \>0.9, the diagnostic accuracy is high enough for a detection method to act as an effective maker. The PLR was 18.33 (\>10), suggesting that it could be used for confirming KRAS gene mutations. The NLR was 0.34 (\>0.1), showing that a negative result was 34% likely to be an FN ([Figure 4](#f4-ott-10-945){ref-type="fig"} and [Table 3](#t3-ott-10-945){ref-type="table"}). The between-study heterogeneity was evaluated by chi-square test (*Q* =53.58, *P*=0.000\<0.05) and I-square test (*I*^2^=96.27, 95% CI =93.48--99.06), which suggested the significantly high heterogeneity. From the likelihood ratio (LR) scattergram, we found that ctDNA was located in the right upper quadrant, indicating ctDNA could be used for confirming KRAS gene mutations ([Figure 5](#f5-ott-10-945){ref-type="fig"}).

Subgroup analysis
-----------------

To determine the effect of potential confounding factors, we performed subgroup analyses measured by AUROC and stratified according to TNM stage, storage method of tumor tissues, blood sample format, ctDNA detection method and detection site of KRAS gene mutation ([Table 3](#t3-ott-10-945){ref-type="table"}). For blood samples, the AUROC was higher in plasma (0.96, 95% CI =0.94--0.97) than in serum (0.83, 95% CI =0.79--0.86), indicating the higher diagnostic accuracy (*P*=0.000\<0.05). With regard to detection methods, ARMS-qPCR was the most frequently used (0.96, 95% CI =0.94--0.97). However, there was no statistically significant difference in diagnostic accuracy between different cancer stages, storage methods of tumor tissues, ctDNA detection method and detection site of KRAS gene mutation.

Discussion
==========

Cancer is the main cause of death, and effective treatment can significantly reduce the mortality of patients with carcinoma. Besides the traditional chemotherapy based on pathological diagnosis, targeted therapy has been widely used according to gene mutation status. Gene evaluation of tumor tissue is the gold standard for assessing mutation status, but it is usually carried out only once because of the invasiveness and costliness. However, genomic alterations may vary in primary and metastatic tumor tissues with the progression of cancer, which need the repetitive genotyping.

As we know, cancer generation and progression are associated with numerous genetic and epigenetic factors, some of which can be detected in gene alternations of tumor tissues. ctDNA, also known as part of cfDNA, can be released into blood and other body fluids from tumor tissues, carrying tumor-related genetic and epigenetic alterations, and can be more informative, specific and accurate than protein biomarkers. Several observations not only suggested the role of DNA in heredity but also provided the evidence for the occurrence of DNA beyond the confinement of cells. In 1977, Leon et al[@b9-ott-10-945] reported that the level of cfDNA in the peripheral blood of cancer patients was notably higher than that in healthy controls, especially in those patients with metastatic sites, and significantly reduced after radiation. In 1994, Sorenson et al[@b35-ott-10-945] and Vasioukhin et al[@b36-ott-10-945] found that RAS gene mutations can be detected in blood cfDNA. As newly improved methods, the detection rate of ctDNA for KRAS and BRAF gene mutations in blood of CRC patients has also been reported in different studies. In 2014, Thierry et al[@b15-ott-10-945] reported that ctDNA showed 98% specificity and 92% sensitivity of KRAS gene mutations and 100% specificity and sensitivity of BRAF gene mutations. Kuo et al[@b20-ott-10-945] pointed out that the detection rate of cfDNA for KRAS gene mutations in plasma was higher (50%) than in primary tumor tissues (28.8%). However, Perrone et al[@b27-ott-10-945] revealed that the KRAS gene mutation rate of cfDNA in plasma was very low (3%) compared to the matched adenocarcinoma tissues (45%). Inconsistent results made the use of ctDNA screening to be unclear. In 2015, Qiu et al[@b14-ott-10-945] compared the diagnostic value of ctDNA for detection of EGFR gene mutations with tumor tissues by a meta-analysis and suggested ctDNA as a highly specific but relatively low-sensitive biomarker in NSCLC patients. In spite of these findings, the clinical utilization of ctDNA for therapeutic monitoring is not yet widespread because of the different results in different studies. Now, we conducted this meta-analysis to suppose the consistency of KRAS gene mutations between ctDNA and the matched tumor tissues in CRC patients, for assessing the possibility of ctDNA used for gene monitoring.

As we know, anti-EGFR MoAb is now restricted to the patients with wild-type KRAS gene.[@b5-ott-10-945] Thus, detection of KRAS gene mutations in CRC patients has become a routine clinical test. Now, we analyzed the diagnostic performance of ctDNA for detection of KRAS gene mutations in CRC patients through meta-analysis in order to assess the clinical value of ctDNA detection. In our meta-analysis, publication bias was assessed by a regression of diagnostic log odds ratio against the inverse of the square root of the effective sample size,[@b37-ott-10-945] and *P*=0.060 for the slope coefficient indicated the absence of publication bias and the accuracy of meta-analysis. Our analysis showed that the overall pooled specificity was 96% and the pooled sensitivity was 67%, which were almost as same as what had been reported for ctDNA for detection of EGFR gene mutations (specificity 96%, sensitivity 62%).[@b14-ott-10-945] According to the guideline of AUROC and DOR,[@b38-ott-10-945] ctDNA detection of KRAS gene mutations also had high diagnostic accuracy and discriminatory value in CRC patients. LR is also used for evaluating diagnostic accuracy and clinical utility of diagnostic test.[@b37-ott-10-945] On basis of the results of PLR and NLR in our analysis, ctDNA was located in the right upper quadrant, indicating that it could be served as a test for confirmation of KRAS gene mutations in CRC patients.

In consideration of the influences of confounding factors on diagnostic accuracy, subgroup analyses were conducted on basis of some common covariates. Many studies have reported that the level of ctDNA was associated with tumor burden and stage.[@b22-ott-10-945],[@b39-ott-10-945],[@b40-ott-10-945] ctDNA has also been reported with a higher diagnostic value for detection of EGFR gene mutations in patients with advanced stage of NSCLC.[@b14-ott-10-945] However, we did not find any significant diagnostic difference for detection of KRAS gene mutation in different stages of CRC patients, which may be due to insufficient data of I--IV stages. The mechanism of release of ctDNAg from tumor cells is not clear, so the level of ctDNA in peripheral blood may not be in accordance with the TNM stage of cancer. That is to say, ctDNA may be useful for CRC patients in different stages. We also did not find the diagnostic accuracy difference of ctDNA between different detection sites of KRAS gene mutation, while may be for the relatively few studies and low mutation rate of codon 13 in CRC patients. In general, ctDNA is obtained from plasma or serum; FFPE or frozen tumor tissue is usually used. Our further stratified analysis indicated that the detection of ctDNA extracted from plasma was more accurate than that from serum, which was consistent with what had been reported in other studies.[@b14-ott-10-945] In 2015, Qiu et al pointed out that ctDNA extracted from plasma had higher diagnostic accuracy than that from serum for detection of EGFR gene mutations in NSCLC patients.[@b14-ott-10-945] Though FFPE may influence the nucleic acids, we still did not find any significant diagnostic accuracy difference of AUROC between FFPE and frozen tumor tissues. What is more, ARMS-qPCR was the most frequently used and had also been proved with high diagnostic performance. The limitations of our meta-analysis were also discussed to reveal the misinterpretation of present results. First, the relatively small size and potentially important differences in subgroup studies may result in statistical biases. Second, our analysis showed high heterogeneity, but none of the present characteristics could declare the heterogeneity. Because of the insufficient reporting of included studies, we could not analyze the probable influence of some potential factors, eg, ethnicity, pathological diagnosis of carcinoma, collection time of blood, chemotherapy situation and the detailed tumor stage, which might be the main sources of heterogeneity. Third, we did not find any significant difference in diagnostic accuracy for KRAS gene mutations after stratified analyses according to cancer stage and the storage method of tumor tissues. These results were in consonance with those studies of ctDNA for detection of other gene mutations, which could be by reason of the relatively few studies and the unclear records in details. Further studies are still needed to account for these issues.

This meta-analysis revealed that ctDNA detection might be useful for repetitive and noninvasive genotyping of KRAS gene mutations in patients with carcinoma, especially for those patients without the opportunity of biopsy at the decision-making points of treatment. This would be an ideal method of gene detection, particularly for cancer patients who are resistant or unable to catch tumor tissues.

Conclusion
==========

ctDNA may help providing information of diagnostic screen, personalized medicine selection and real-time monitoring for cancer patients.

This study was supported by the funding from First Affiliated Hospital of Chinese People's Liberation Army General Hospital. We would like to thank Doctor Jianhua Zhu, Doctor Guanghui Li and Doctor He Zhang for their help and support in study work.

**Disclosure**

The authors report no conflicts of interest in this work.

![A flow chart showing the studies included in this meta-analysis.](ott-10-945Fig1){#f1-ott-10-945}

![The Deeks regression line showing the publication bias of studies.\
**Abbreviations:** ESS, effective sample size; DOR, diagnostic odds ratio.](ott-10-945Fig2){#f2-ott-10-945}

![The SROC curve of ctDNA for detection of KRAS gene mutations.\
**Abbreviations:** SROC, summary receiver operating characteristic; AUC, area under the curve.](ott-10-945Fig3){#f3-ott-10-945}

![Fagan's nomogram of ctDNA for detection of KRAS gene mutations.\
**Abbreviation:** LR, likelihood ratio.](ott-10-945Fig4){#f4-ott-10-945}

![LR scattergram of ctDNA for detection of KRAS gene mutations.\
**Abbreviations:** LR, likelihood ratio; NLR, negative likelihood ratio; PLR, positive likelihood ratio; CI, confidence interval; LUQ, left upper quadrant; LRP, likelihood ratio for positive results; RUQ, right upper quadrant; LLQ, left lower quadrant; RLQ, right lower quadrant; LRN, likelihood ratio for negative results.](ott-10-945Fig5){#f5-ott-10-945}

###### 

Characteristics of eligible studies

  First author                        Year   Country           Patients   TNM        Tissue   Blood    Collection   Method            Codon    Sensitivity   Specificity   TP    FN   FP   TN
  ----------------------------------- ------ ----------------- ---------- ---------- -------- -------- ------------ ----------------- -------- ------------- ------------- ----- ---- ---- -----
  Bettegowda et al[@b16-ott-10-945]   2014   Multi             206        Advanced   NA       Plasma   NA           dPCR              12, 13   0.872         0.992         68    10   1    127
  Danese et al[@b17-ott-10-945]       2015   Italy             85         I--IV      Frozen   Plasma   Before       ARMS-qPCR         12, 13   0.815         0.931         22    5    4    54
  Kim et al[@b18-ott-10-945]          2015   Korea             65         Advanced   FFPE     Serum    NA           RFLP-PCR          12, 13   0.581         0.765         18    13   8    26
  Kopreski et al[@b19-ott-10-945]     2000   USA               135        NA         FFPE     Plasma   Before       RFLP-PCR          12       0.829         0.930         29    6    7    93
  Kuo et al[@b20-ott-10-945]          2014   China             52         I--IV      NA       Plasma   NA           PNA-PCR           12, 13   1.000         0.703         15    0    11   26
  Lefebure et al[@b21-ott-10-945]     2010   France            24         IV         NA       Serum    NA           Real-time PCR     12, 13   0.500         1.000         7     7    0    10
  Lin et al[@b22-ott-10-945]          2014   China             133        I--IV      Frozen   Plasma   Before       MassARRAY         12, 13   0.456         1.000         41    49   0    43
  Liu et al[@b23-ott-10-945]          2012   China             62         NA         Frozen   Plasma   Before       Nested cold-PCR   12       0.750         0.920         9     3    4    46
  Miyano et al[@b24-ott-10-945]       2012   Japan             42         I--IV      FFPE     Plasma   Before       PNA-PCR           12, 13   0.615         0.931         8     5    2    27
  Morgan et al[@b25-ott-10-945]       2012   USA               71         IV         FFPE     Plasma   Before       ARMS-qPCR         12, 13   0.313         0.949         10    22   2    37
  Morgan et al[@b25-ott-10-945]       2012   USA               71         IV         FFPE     Serum    Before       ARMS-qPCR         12, 13   0.281         1.000         9     23   0    39
  Mulcahy et al[@b26-ott-10-945]      2000   Switzerland       14         NA         NA       Plasma   Before       MASA-PCR          12       0.857         1.000         6     1    0    7
  Perrone et al[@b27-ott-10-945]      2014   Italy             12         NA         FFPE     Plasma   Before       ME-PCR            12, 13   0.000         1.000         0     5    0    7
  Pu et al[@b28-ott-10-945]           2013   China             115        I--IV      FFPE     Serum    Before       Nested PCR        12, 13   0.243         0.949         9     28   4    74
  Ryan et al[@b29-ott-10-945]         2003   the Netherlands   78         I--IV      FFPE     Serum    Before       ME-PCR            12, 13   0.756         0.973         31    10   1    36
  Sakai et al[@b30-ott-10-945]        2015   Japan             15         NA         FFPE     Plasma   NA           NGS               12, 13   0.714         1.000         5     2    0    8
  Sefrioui et al[@b31-ott-10-945]     2015   France            34         IV         FFPE     Plasma   Before       dPCR              12, 13   0.688         1.000         11    5    0    18
  Spindler et al[@b32-ott-10-945]     2015   Denmark           211        IV         FFPE     Plasma   Before       ARMS-qPCR         12, 13   0.800         0.958         112   28   3    68
  Taly et al[@b33-ott-10-945]         2013   France            50         IV         Frozen   Plasma   NA           qPCR              12, 13   0.789         0.935         15    4    2    29
  Thierry et al[@b15-ott-10-945]      2014   France            95         IV         NA       Plasma   NA           qPCR              12, 13   0.923         0.982         36    3    1    55
  Xu et al[@b34-ott-10-945]           2014   China             242        IV         FFPE     Plasma   Before       PNA-PCR           12, 13   0.547         0.904         64    53   12   113

**Abbreviations:** TNM, tumor--node--metastasis; TP, true positive; FN, false negative; FP, false positive; TN, true negative; NA, not applicable; dPCR, digital polymerase chain reaction; ARMS-qPCR, allele refractory mutation system -- quantitative polymerase chain reaction; FFPE, formalin-fixed and paraffin-embedded; RFLP-PCR, restriction fragment length polymorphism -- polymerase chain reaction; PNA-PCR, peptide nucleic acid-mediated polymerase chain reaction; PCR, polymerase chain reaction; MASA-PCR, mutant specific alleles -- polymerase chain reaction; ME-PCR, mutant-enriched polymerase chain reaction, NGS, next-generation sequencing; qPCR, quantitative polymerase chain reaction.

###### 

QUADAS-2 score of eligible studies

  First author                        Risk of bias   Application concerns                   
  ----------------------------------- -------------- ---------------------- --- --- --- --- ---
  Bettegowda et al[@b16-ott-10-945]   L              U                      U   L   L   L   L
  Danese et al[@b17-ott-10-945]       L              U                      U   L   L   L   L
  Kim et al[@b18-ott-10-945]          L              U                      U   L   L   L   L
  Kopreski et al[@b19-ott-10-945]     L              U                      U   L   L   L   L
  Kuo et al[@b20-ott-10-945]          L              U                      U   L   L   L   L
  Lefebure et al[@b21-ott-10-945]     L              U                      U   L   L   L   L
  Lin et al[@b22-ott-10-945]          L              L                      L   L   L   L   L
  Liu et al[@b23-ott-10-945]          L              U                      U   L   L   L   L
  Miyano et al[@b24-ott-10-945]       L              U                      U   L   L   L   L
  Morgan et al[@b25-ott-10-945]       L              L                      L   L   L   L   L
  Morgan et al[@b25-ott-10-945]       L              L                      L   L   L   L   L
  Mulcahy et al[@b26-ott-10-945]      L              U                      U   L   L   L   L
  Perrone et al[@b27-ott-10-945]      L              U                      U   L   L   L   L
  Pu et al[@b28-ott-10-945]           L              U                      U   L   L   L   L
  Ryan et al[@b29-ott-10-945]         L              U                      U   L   L   L   L
  Sakai et al[@b30-ott-10-945]        L              U                      U   L   L   L   L
  Sefrioui et al[@b31-ott-10-945]     L              H                      L   L   L   L   L
  Spindler et al[@b32-ott-10-945]     L              L                      L   L   L   L   L
  Taly et al[@b33-ott-10-945]         L              U                      U   L   L   L   L
  Thierry et al[@b15-ott-10-945]      L              U                      U   L   L   L   L
  Xu et al[@b34-ott-10-945]           L              L                      L   L   L   L   L

**Abbreviations:** L, low; U, unclear; H, high; QUADAS-2, quality assessment of studies of diagnostic accuracy included in systematic reviews-2.

###### 

Meta-analysis of subgroup

  Subgroup analyses   n    Sensitivity         Specificity         AUROC               DOR                     PLR                    NLR
  ------------------- ---- ------------------- ------------------- ------------------- ----------------------- ---------------------- -------------------
  All                 21   0.67 (0.55--0.78)   0.96 (0.93--0.98)   0.95 (0.92--0.96)   53.95 (26.24--110.92)   18.33 (10.14--33.16)   0.34 (0.24--0.49)
  TNM stage                                                                                                                           
   Advanced           10   0.66 (0.50--0.79)   0.97 (0.93--0.99)   0.95 (0.93--0.97)   71.52 (21.18--241.57)   24.88 (9.36--66.17)    0.35 (0.22--0.54)
   I--IV              6    0.73 (0.40--0.92)   0.93 (0.86--0.97)   0.94 (0.92--0.96)   37.80 (14.18--100.79)   11.02 (6.18--19.66)    0.29 (0.11--0.77)
  Storage of tissue                                                                                                                   
   FFPE               12   0.55 (0.40--0.69)   0.96 (0.92--0.98)   0.93 (0.90--0.95)   29.19 (12.47--68.33)    13.63 (6.88--27.01)    0.47 (0.34--0.65)
   Frozen             4    0.70 (0.51--0.84)   0.95 (0.88--0.98)   0.94 (0.91--0.96)   48.17 (18.44--125.87)   15.07 (6.29--36.09)    0.31 (0.18--0.54)
  Format of blood                                                                                                                     
   Plasma             16   0.74 (0.60--0.84)   0.97 (0.93--0.98)   0.96 (0.94--0.97)   77.45 (39.03--153.72)   20.93 (11.58--37.82)   0.27 (0.17--0.43)
   Serum              5    0.47 (0.29--0.66)   0.96 (0.84--0.99)   0.83 (0.79--0.86)   22.16 (4.30--114.30)    12.25 (2.69--55.84)    0.55 (0.39--0.79)
  Detection method                                                                                                                    
   ARMS-qPCR          4    0.58 (0.30--0.81)   0.96 (0.91--0.98)   0.96 (0.94--0.97)   34.90 (11.17--109.07)   15.38 (6.96--34.01)    0.44 (0.23--0.85)
  Detection site                                                                                                                      
   Codon 12           21   0.67 (0.55--0.78)   0.96 (0.93--0.98)   0.95 (0.92--0.96)   53.95 (26.24--110.92)   18.33 (10.14--33.16)   0.34 (0.24--0.49)
   Codon 12, 13       18   0.65 (0.50--0.77)   0.97 (0.93--0.99)   0.95 (0.92--0.96)   55.56 (23.97--128.81)   20.26 (9.97--41.18)    0.37 (0.25--0.54)

**Note:** Data presented as n (95% confidence interval).

**Abbreviations:** AUROC, area under the ROC curve; DOR, diagnostic odds ratio; PLR, positive likelihood ratio; NLR, negative likelihood ratio; TNM, tumor--node--metastasis; FFPE, formalin-fixed and paraffin-embedded; ARMS-qPCR, allele refractory mutation system -- quantitative polymerase chain reaction.
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